U.S. Markets open in 7 hrs 29 mins

Oragenics Fast Track Drug AG013 Going into Phase II Clinicals, Pipeline Review

NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Oragenics, Inc. (OGEN) a company focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.

OGEN's product AG013, which has been granted Fast Track designation with the U.S. Food and Drug Administration and orphan drug status in Europe, is an Intrexon Actobiotics therapeutic candidate formulated to deliver the therapeutic molecule, human Trefoil Factor 1, to the mucosal tissues in the oral cavity in a convenient oral rinsing solution.

OGEN pipeline and the potential market for AG013 here READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/oragenics/

Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

Upcoming OGEN milestones and more in the full report, no obligation READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/oragenics/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source